{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:54:12Z","timestamp":1783619652739,"version":"3.55.0"},"reference-count":103,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1080\/13543776.2016.1217331","type":"journal-article","created":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T15:05:56Z","timestamp":1469459156000},"page":"1307-1323","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic compounds for Cushing\u2019s syndrome: a patent review (2012-2016)"],"prefix":"10.1080","volume":"26","author":[{"given":"Li","family":"Ma","sequence":"first","affiliation":[{"name":",","place":["China PR"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Yin","sequence":"additional","affiliation":[{"name":"Haverhill, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhong","family":"Hu","sequence":"additional","affiliation":[{"name":",","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,7,30]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61375-1"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2014.282871"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0645-6"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345431"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1942"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2011.10.013"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3200"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S44336"},{"key":"e_1_3_3_11_1","first-page":"2664","article-title":"Persistence of increased cardiovascular risk in patients with Cushing\u2019s disease after five years of successful cure","volume":"84","author":"Colao A","year":"1999","unstructured":"Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing\u2019s disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84:2664\u20132672.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04206.x"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000314293"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000317716"},{"key":"e_1_3_3_15_1","unstructured":"Regents of the University of Minnesota. Ergoline derivatives as dopamine receptor modulators. WO2014078857. 2014."},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1294.012"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00004.2005"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12431"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0557-2"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105743"},{"key":"e_1_3_3_21_1","unstructured":"Ipsen Pharma S.A.S. Somatostatin analogs and dimers thereof. WO2014070965. 2014."},{"key":"e_1_3_3_22_1","unstructured":"Glytech Inc. Glycosylated polypeptide and drug composition containing said polypeptide. WO2013032012. 2013."},{"key":"e_1_3_3_23_1","unstructured":"Indus Biotech Private Limited. A method of managing hypercortisolemia headache disorders neuropathic pain and related disorders. WO2012164356. 2012."},{"key":"e_1_3_3_24_1","unstructured":"Indus Biotech Private Limited. A composition for selective serotonin reuptake inhibition and process thereof. WO2008099426. 2008."},{"key":"e_1_3_3_25_1","unstructured":"Alder Biopharmaceuticals Inc. Anti-ACTH antibodies and use thereof. WO2015127288. 2015."},{"key":"e_1_3_3_26_1","unstructured":"Colorado seminary which owns and operates the Univeristy of Denver. Methods of treating overproduction of cortisol using ACTH antagonist peptides. US8524664. 2013."},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfl051"},{"key":"e_1_3_3_28_1","volume-title":"Neidle S, editor. Cancer drug design and discovery","author":"Hu Q","unstructured":"Hu Q, Hartmann RW. The renaissance of CYP17 inhibitors for the treatment of prostate cancer. In: Neidle S, editor. Cancer drug design and discovery. London: Academic Press; 2014. p. 319\u2013356.","edition":"2014"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1818"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00093a015"},{"issue":"1","key":"e_1_3_3_31_1","first-page":"S88","article-title":"Differential effects of co-administration of racemic ketoconazole and levdexketoconazole on the pharmacokinetic profile of atorvastatin","volume":"83","author":"Boudriau S","year":"2008","unstructured":"Boudriau S, Demnati R, Swearingen D, et al. Differential effects of co-administration of racemic ketoconazole and levdexketoconazole on the pharmacokinetic profile of atorvastatin. Clin Pharmacol Ther. 2008;83(S1):S88.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_3_32_1","unstructured":"Treatment for endogenous Cushing\u2019s syndrome. [cited 2016 April 26]. Available from: clinicaltrials.gov\/ct2\/show\/NCT01838551."},{"key":"e_1_3_3_33_1","unstructured":"Cortendo AB (Publ). Methods and compositions for the treatment of Cushing\u2019s syndrome using 2S 4R ketoconazole. WO2016048984. 2016."},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903381411"},{"key":"e_1_3_3_35_1","unstructured":"Cortendo AB (Publ). Novel functionalized 4-(phenoxymethyl(\u22121 3-dioxolane analogs exhibiting cytochrome p450 inhibition and their method of use. WO2014122530. 2014."},{"key":"e_1_3_3_36_1","unstructured":"Cortendo AB (Publ). Novel functionalized 5-(phenoxymethyl)-1 3-dioxane analogs exhibiting cytochrome P450 inhibition. WO2015048311. 2015."},{"key":"e_1_3_3_37_1","unstructured":"Cortendo AB (Publ). Novel cytochrome p450 inhibitors and their method of use. WO2015039036. 2015."},{"key":"e_1_3_3_38_1","unstructured":"Cortendo AB (Publ). Novel cytochrome p450 inhibitors and their method of use. US2015210641. 2015."},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100400a"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100317b"},{"key":"e_1_3_3_41_1","unstructured":"Cortendo AB (Publ). Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction. WO2014111815. 2014."},{"key":"e_1_3_3_42_1","unstructured":"British Technology Group Ltd. 17-substituted steroids useful in cancer treatment. WO1993020097. 1993."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2013.274"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14406"},{"key":"e_1_3_3_45_1","unstructured":"Biomarin Pharmaceutical Inc. CYP11B CYP17 and\/or CYP21 inhibitors. WO2012083112. 2012."},{"key":"e_1_3_3_46_1","unstructured":"Novartis AG Imidazole derivatives as aldosterone synthase inhibitors. WO2011064376. 2011."},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401430e"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml400324c"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.37.GP.22.05"},{"key":"e_1_3_3_50_1","unstructured":"Novartis AG Use of an adrenal hormonemodifying agent. WO2011088188. 2011."},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2117"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0692-z"},{"key":"e_1_3_3_53_1","unstructured":"Safety and Efficacy of LCI699 for the treatment of patients with Cushing\u2019s disease. [cited 2016 April 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02180217."},{"key":"e_1_3_3_54_1","unstructured":"Universitaet Des Saarlandes. Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases. WO2012052540. 2012."},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml100283h"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2008.07.011"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201000065"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm400240r"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.04.013"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm3003872"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm501004t"},{"key":"e_1_3_3_62_1","unstructured":"Corcept Therapeutics Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators. WO2013130420. 2013."},{"key":"e_1_3_3_63_1","unstructured":"Corcept Therapeutics Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators. WO2013177559. 2013."},{"key":"e_1_3_3_64_1","unstructured":"Corcept Therapeutics Inc. Octahydro fused azadecalin glucocorticoid receptor modulators. WO2015077530. 2015."},{"key":"e_1_3_3_65_1","unstructured":"Corcept Therapeutics Inc. Heteroaryl-ether fused azadecalin glucocorticoid receptor modulators. WO2015077537. 2015."},{"key":"e_1_3_3_66_1","unstructured":"Corcept Therapeutics Inc. Pyrimidine cyclohexyl glucocorticoid receptor modulators. WO2012129074. 2012."},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-7970com"},{"key":"e_1_3_3_68_1","unstructured":"Bayer Pharma Aktiengesellschaft. Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity. WO2012059594. 2012."},{"key":"e_1_3_3_69_1","unstructured":"Max-Planck-Gesellschaft zur F\u00f6rderung der Wissenschaft e.V. C-terminal hsp90 inhibitors to treat pituitary adenomas. WO2014106623. 2014."},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.09.024"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.03.012"},{"key":"e_1_3_3_72_1","unstructured":"Cedars-Sinai Medical Center. Treatment of pituitary corticotroph tumors using R-roscovitine. WO2012061601. 2012."},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1606"},{"key":"e_1_3_3_74_1","unstructured":"Treatment of Cushing\u2019s disease with R-roscovitine. [cited 2016 May 6]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02160730."},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2014.09.008"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.11.158"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1177\/019262339302100107"},{"key":"e_1_3_3_78_1","unstructured":"The Regents Of The University Of Michigan Atterocor Inc. Compounds and methods for treating aberrant adrenocartical cell disorders. WO2013142214. WO2013."},{"key":"e_1_3_3_79_1","unstructured":"Atterocor Inc. Treating disorders associated with aberrant adrenocortical cell behavior. WO2015048543. 2015."},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0527"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-2052"},{"key":"e_1_3_3_82_1","unstructured":"Phase 1 study of ATR-101 in subjects with advanced adrenocortical carcinoma. [cited 2016 May 6]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01898715."},{"key":"e_1_3_3_83_1","unstructured":"Targeted therapy with gefitinib in patients with USP8-mutated Cushing\u2019s disease. [cited 2016 May 6]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02484755."},{"key":"e_1_3_3_84_1","unstructured":"Targeted therapy with lapatinib in patients with recurrent pituitary tumors resistant to standard therapy. [cited 2016 May 6]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00939523."},{"key":"e_1_3_3_85_1","unstructured":"Cedars-Sinai Medical Center. Use of tyrosine kinase inhibitors for treatment of cushing\u2019s disease and hypercortisolism. WO2011094722. 2011."},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1771"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600840203"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2012.1244"},{"key":"e_1_3_3_89_1","first-page":"671","article-title":"Possible mechanism and treatment of o,p\u2019DDD-induced hypercholesterolaemia","volume":"84","author":"Maher VM","year":"1992","unstructured":"Maher VM, Trainer PJ, Scoppola A, et al. Possible mechanism and treatment of o,p\u2019DDD-induced hypercholesterolaemia. Q J Med. 1992;84:671\u2013679.","journal-title":"Q J Med"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0670"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3350"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-007-9128-9"},{"key":"e_1_3_3_93_1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0022-3565(25)22688-X","article-title":"Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells","volume":"240","author":"Lamberts SW","year":"1987","unstructured":"Lamberts SW, Bons EG, Bruining HA, et al. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther. 1987;240:259\u221264.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0913"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0536"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.21.3.245"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1093484"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0477"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.110"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-17906"},{"key":"e_1_3_3_101_1","first-page":"P953","article-title":"Androgens profile in Cushing\u2019s disease with hirsutism","volume":"29","author":"Haouat E","year":"2012","unstructured":"Haouat E, Salem LB, Kamoun I, et al. Androgens profile in Cushing\u2019s disease with hirsutism. Endocr Abstr. 2012;29:P953.","journal-title":"Endocr Abstr"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310359"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1249480"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2956"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1252328"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2016.1217331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:49:41Z","timestamp":1772765381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2016.1217331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,30]]},"references-count":103,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1080\/13543776.2016.1217331"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2016.1217331","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}